SLC39A3 and age-related macular degeneration: The inclusion of a vitamin C transporter (SLC23A1) and a zinc transporter (SLC39A3) within the signature was of particular interest, in light of the Age-Related Eye Disease Research Group study that demonstrated supplementation with zinc and anti-oxidants, including vitamin C, lowered the probability of developing neovascular ARMD in some high-risk patient subgroups [45].